Measuring quality of life in muscular dystrophy

OBJECTIVES:The objectives of this study were to develop a conceptual model of quality of life (QOL) in muscular dystrophies (MDs) and review existing QOL measures for use in the MD population. METHODS:Our model for QOL among individuals with MD was developed based on a modified Delphi process, liter...

Full description

Saved in:
Bibliographic Details
Published in:Neurology Vol. 84; no. 10; pp. 1034 - 1042
Main Authors: Bann, Carla M, Abresch, Richard T, Biesecker, Barbara, Conway, Kristin Caspers, Heatwole, Chad, Peay, Holly, Scal, Peter, Strober, Jonathan, Uzark, Karen, Wolff, Jodi, Margolis, Marjorie, Blackwell, Angela, Street, Natalie, Montesanti, Angela, Bolen, Julie
Format: Journal Article
Language:English
Published: United States American Academy of Neurology 10-03-2015
Lippincott Williams & Wilkins
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVES:The objectives of this study were to develop a conceptual model of quality of life (QOL) in muscular dystrophies (MDs) and review existing QOL measures for use in the MD population. METHODS:Our model for QOL among individuals with MD was developed based on a modified Delphi process, literature review, and input from patients and patient advocacy organizations. Scales that have been used to measure QOL among patients with MD were identified through a literature review and evaluated using the COSMIN (Consensus-Based Standards for the Selection of Health Measurement Instruments) checklist. RESULTS:The Comprehensive Model of QOL in MD (CMQM) captures 3 broad domains of QOL (physical, psychological, and social), includes factors influencing self-reported QOL (disease-related factors, support/resources, and expectations/aspirations), and places these concepts within the context of the life course. The literature review identified 15 QOL scales (9 adult and 6 pediatric) that have been applied to patients with MD. Very few studies reported reliability data, and none included data on responsiveness of the measures to change in disease progression, a necessary psychometric property for measures included in treatment and intervention studies. No scales captured all QOL domains identified in the CMQM model. CONCLUSIONS:Additional scale development research is needed to enhance assessment of QOL for individuals with MD. Item banking and computerized adaptive assessment would be particularly beneficial by allowing the scale to be tailored to each individual, thereby minimizing respondent burden.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
ISSN:0028-3878
1526-632X
DOI:10.1212/WNL.0000000000001336